Founded December 2011
Investor The Trendlines Group
CEO Assaf Livne
LapSpace’s inflatable balloon retractor has proven itself in animal trials for better and more efficient retraction of organs such as the intestines.
Deployed through a standard trocar and inflated inside the abdominal cavity, the retractor gently and effectively “catches” and retracts the organs to create a stable operating field. When the procedure is completed, the device is deflated and removed through the entry port.
The retractor’s self-retaining clamp allows it to remain in place for long periods of time, without the need for additional surgical personnel.
The LapSpace inflatable retractor greatly improves efficiency and decreases the cost of the surgery.
The market requires a simple, safe retraction technique.
U.S. and EU: ~10 million laparoscopic procedures • Initial sales in Europe • Successful study at Johns Hopkins • FDA cleared, CE mark
See the LapSpace retractor in use in live surgeries.
LapSpace CEO Assaf Livne presents at Trendlines Showcase.
Assaf Livne brings prior business development and marketing experience from positions at Johnson & Johnson, specializing in minimally invasive solutions, and Cheetah Medical, an Israeli start-up company. He received an MA in finance and budget management from Tel Aviv University.
Zeev Bronfeld has raised hundreds of millions of dollars for early-stage companies and has a proven track record of shareholder value creation and exits. He founded and serves as director of Biomedix (TASE: BMDX). He founded Biocell (TASE: BCEL), a company specializing in biotechnology, where he has served as a director and CEO since 1986. He is also a director of D. Medical Industries (TASE: DMDC) and Protalix (AMEX: PLX).
Dr. Hien Nguyen is an assistant professor of surgery at the Johns Hopkins University School of Medicine, where he specializes in minimally invasive surgery, single incision surgery, robotic surgery, laparoscopic bariatric surgery (Roux-en-Y gastric bypass, adjustable gastric bands, sleeve gastrectomy and duodenal switch), minimally invasive repair of complex hernias, and general surgery. His pioneering work at Johns Hopkins includes a number of “firsts”: single-incision laparoscopic cholecystectomy, robotic gastric bypass, and endoscopic component separation.
Dr. Eliad Karin is a senior attending surgeon in the General Surgery Department at Sourasky Medical Center, Tel Aviv, Israel. He specializes in general and laparoscopic surgery, hernia and abdominal wall reconstruction.
Gilad Lavi has extensive experience in medical device R&D from early research and POC through prototype design and manufacturing support. His focus includes laparoscopic and arthroscopic surgical tools (NovoLap, MinInvasive), drug delivery technologies (Elan Medical), NOTES (ObesiTx), and medical cosmetics (Capula Medical).
Laparoscopic procedures have become the new surgical standard in the last decade. The success of laparoscopic procedures, however, depends on optimal exposure of the operating site. Advantages include smaller incisions, quicker recovery, less scarring, lower infection rates, less post-surgical pain, and shorter hospital stays.
Currently, abdominal organs obstructing the view are inefficiently retracted from the target organ. This leads to an unstable field that does not create a large enough working space, increasing the risk of injury to surrounding tissue, and complication rates.
The current method of creating space includes tilting the entire operating room table at steep angles to allow some organs to “fall away.” If this does not work, then the delicate organs are pushed and pulled away with jagged-tooth graspers that require additional ports and personnel. These inefficient methods lead to inconsistent retraction and longer operating times as well as potential complications such as bowel perforation, bleeding, bruising, and falling.
According to research conducted by LapSpace, there are over 4 million laparoscopic procedures performed annually in the United States.
LapSpace estimates that 2 million of these procedures, or 50%, could benefit from its proprietary inflatable laparoscopic retractor.